爱尔兰将药物核准时间缩短514天,在2026年加快了32种新药品的获取速度。 Ireland to cut drug approval time by 514 days, speeding access to 32 new medicines in 2026.

爱尔兰将批准一项为期四年的药品协定,将新药的平均批准时间从617天缩短为180天,满足法定要求。 Ireland is set to approve a four-year medicines agreement that will cut the average approval time for new drugs from 617 to 180 days, meeting a legal requirement. 这项涉及政府、制药公司和通用制造商的交易旨在将延误,特别是癌症治疗方面的延误减少514天。 The deal, involving the government, pharmaceutical companies, and generic manufacturers, aims to reduce delays, especially for cancer treatments, by 514 days. 预计到2026年,它将为病人带来32种新药品,包括癌症、糖尿病和心脏病药品。 It is expected to bring about 32 new medicines to patients in 2026, including those for cancer, diabetes, and heart disease. 爱尔兰病人协会欢迎这一举动,认为这是朝着消除私人与公共病人之间在获得治疗机会方面的差距迈出的一步。 The Irish Patients Association welcomed the move as a step toward ending disparities in access between private and public patients. 为确保问责制和核实改进情况,将需要定期公开报告毒品获取和等候时间的情况。 Regular public reporting on drug access and waiting times will be required to ensure accountability and verify improvements.